SAVI applicator removes obstacles associated with brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

TORONTO-Studies out of the University of California, San Diego, have demonstrated that the SAVI radiation device offers coverage of the breast cancer tumor bed while sparing normal tissue from radiation.

TORONTO-Studies out of the University of California, San Diego, have demonstrated that the SAVI radiation device offers coverage of the breast cancer tumor bed while sparing normal tissue from radiation.

There were no infections, persistent seromas, or local recurrences of cancer among any of the patients in two separate investigations conducted by Daniel Scanderbeg, PhD, and Catheryn Yashar, MD, both from the university's Moores Cancer Center. They presented their findings at the 2009 American Brachytherapy Society meeting. Dr. Scanderbeg's group retrospectively evaluated 13 breast cancer patients with breast cancer tumor cavities less than 7 mm from the skin surface.

Dr. Yashar's team reviewed early clinical experiences with SAVI in 40 breast cancer patients, nearly half of whom were not candidates for balloon brachytherapy due to skin spacing or small tumor size. They concluded that the device allowed for planning flexibility, easier insertion, and minimal exposure.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.